Immunic (IMUX) Profit After Tax (2013 - 2026)

Immunic has disclosed Profit After Tax across 14 years of filings, most recently posting -$32.6 million for Q1 2026.

• Profit After Tax for Q1 2026 came in at -$32.6 million, down 27.93% year-over-year; the trailing twelve-month figure through Mar 2026 was -$104.3 million (down 8.19% YoY), and the FY2025 annual result was -$97.2 million, up 3.32% from the prior year.
• Profit After Tax came in at -$32.6 million for Q1 2026 at Immunic, down from -$19.3 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$19.3 million in Q4 2025 to a low of -$56.5 million in Q4 2022.
• The 5-year median for Profit After Tax is -$24.4 million (2024), against an average of -$26.1 million.
• Across the five-year window, Profit After Tax slumped 166.58% in 2022 and surged 61.8% in 2023, its largest moves.
• Immunic's Profit After Tax stood at -$56.5 million in 2022, then soared by 61.8% to -$21.6 million in 2023, then fell by 16.7% to -$25.2 million in 2024, then rose by 23.34% to -$19.3 million in 2025, then slumped by 68.85% to -$32.6 million in 2026.
• The last three Profit After Tax figures came in at -$32.6 million (Q1 2026), -$19.3 million (Q4 2025), and -$25.6 million (Q3 2025), per Business Quant data.